Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology

BARCELONA, Spain & NIEL, Belgium, December 12, 2023--Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Related Keywords

Belgium ,United States ,Boston ,Massachusetts ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Spanish ,Karl Ziegelbauer ,Richard Hayhurst ,Bernard Sagaert ,Omar Ram ,Spanish Stock Exchange ,Corporate Communications ,Chief Scientific Officer ,Noble Purpose ,Almirall ,Snp ,Global Pharmaceutical Company ,Skin Diseases ,Etherna ,Rna ,Research And Development ,Technology Platform Company ,